<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03991442</url>
  </required_header>
  <id_info>
    <org_study_id>BR-FAHC-CT-301</org_study_id>
    <nct_id>NCT03991442</nct_id>
  </id_info>
  <brief_title>BR1010 in Patients With Essential Hypertension Patients Who do Not Adequately Respond to Fimasartan/Amlodipine Combination</brief_title>
  <acronym>FINAL</acronym>
  <official_title>A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of BR1010 in Essential Hypertension Patients Who do Not Adequately Respond to Fimasartan/Amlodipine Combination</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boryung Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boryung Pharmaceutical Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this clinical study is to evaluate the efficacy and safety by comparing the
      BR1010 treatment group to the fimasartan/amlodipine treatment group at Week 8 in patients
      with essential hypertension who do not adequately respond to Fimasartan/Amlodipine
      combination
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 17, 2019</start_date>
  <completion_date type="Anticipated">September 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>sitting systolic blood pressure</measure>
    <time_frame>8weeks from Baseline Visit</time_frame>
    <description>The change of sitting systolic blood pressure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>sitting systolic blood pressure</measure>
    <time_frame>2weeks and 4weeks from Baseline Visit</time_frame>
    <description>The change of sitting systolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sitting systolic blood pressure and sitting diastolic blood pressure</measure>
    <time_frame>2weeks, 4weeks and 8weeks from Baseline Visit</time_frame>
    <description>The change of sitting systolic blood pressure and sitting diastolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The ratio of subjects who get normalized blood pressure</measure>
    <time_frame>2weeks, 4weeks and 8weeks from Baseline Visit</time_frame>
    <description>The ratio of subjects who get normalized blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rate</measure>
    <time_frame>2weeks, 4weeks and 8weeks from Baseline Visit</time_frame>
    <description>Response Rate</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Essential Hypertension</condition>
  <arm_group>
    <arm_group_label>BR1010 and Fimasartan/Amlodipine placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BR1010 or Fimasartan/Amlodipine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BR1010 placebo and Fimasartan/Amlodipine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>BR1010 or Fimasartan/Amlodipine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fimasartan/Amlodipine</intervention_name>
    <description>Active Comparator: a fixed dose combination of Fimasartan/Amlodipine or placebo</description>
    <arm_group_label>BR1010 and Fimasartan/Amlodipine placebo</arm_group_label>
    <arm_group_label>BR1010 placebo and Fimasartan/Amlodipine</arm_group_label>
    <other_name>BR1010 or placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1.Voluntarily provided a written consent to participate in this clinical study 2.19 years
        old or above Koreans living in Korea 3.Patients with uncontrolled essential hypertension at
        screening time(Visit 1)

          -  Use antihypertensive drugs:140 mmHg ≤ sitSBP &lt; 200 mmHg

          -  Naïve: 160 mmHg ≤ sitSBP &lt; 200 mmHg 4.Patients with uncontrolled hypertension after
             Fimasartan/Amlodipine 30/5mg treatment for 4 weeks at randomization(Visit 2) (Selected
             Arm:140 mmHg ≤ sitSBP &lt; 200 mmHg 5.Able to understand this study, be cooperative in
             the execution of the study, and participate in the study until its completion

        Exclusion Criteria:

          1. Difference of SiSBP ≥ 20 mmHg and SiDBP ≥ 10 mmHg in 3 blood pressure measurements in
             the selected reference arm at the screening visit

          2. Blood pressure results showing sitDBP ≥ 120 mmHg at screening and baseline visit(Visit
             1; Both Arm, Visit 2: Selected Arm)

          3. Treatment Compliance of Fimasartan/Amlodipine 30/5mg &lt; 70%

          4. Heart failure(New York Heart Association class 3 and 4), ischemic heart disease,
             peripheral vascular disease

          5. Percutaneous Coronary Artery within 6 months prior to study

          6. Clinically significant ventricular tachycardia, atrial fibrillation, atrial flutter;
             or other arrhythmia conditions that are determined to be clinically significant by the
             investigator

          7. Patients who have history of severe cerebrovascular disease within 6 months prior to
             study

          8. Type I Diabetes Mellitus or Uncontrolled Type II Diabetes Mellitus(HbA1c &gt; 9% at
             screening visit

          9. Patients who have history of severe or malignant retinopathy within 6 months prior to
             study

         10. Pregnant or lactating women

         11. Planning pregnancy during the study period or have childbearing potential but are not
             using acceptable contraceptive methods

         12. Patients taking other clinical trial drugs within 4 weeks from the time of visit for
             screening

         13. Patients who are judged unsuitable to participate in this study by investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bong-Seog KIM</last_name>
    <phone>82-2-708-8024</phone>
    <email>seog9270@boryung.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Boryung Pharmaceutical Co., Ltd</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>HWA-YEON SHIN</last_name>
      <phone>82-2-708-8069</phone>
      <email>hshin@boryung.co.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>June 17, 2019</study_first_submitted>
  <study_first_submitted_qc>June 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2019</study_first_posted>
  <last_update_submitted>April 6, 2020</last_update_submitted>
  <last_update_submitted_qc>April 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Essential Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

